10-Q: Medtronic Reports Strong Q2 Growth, Diabetes Spinoff On Track

Medtronic plc announced robust financial results for the second quarter and first half of fiscal year 2026, driven by strong segment performance and progress on its Diabetes business separation.

Summary

• Net sales for the three months ended October 24, 2025, increased by 7% to $8.96 billion, up from $8.40 billion in the prior year.
• Net sales for the six months ended October 24, 2025, rose by 8% to $17.54 billion, compared to $16.32 billion in the previous year.
• Net income attributable to Medtronic for the quarter grew 8.2% to $1.37 billion, up from $1.27 billion.
• Diluted earnings per share (EPS) for the quarter increased by 8.1% to $1.07, compared to $0.99 in the prior year.
• Operating profit for the quarter was $1.69 billion, a 5.7% increase from $1.60 billion in the same period last year.
• The effective tax rate for the quarter decreased to 13.5% from 18.0% in the prior year, primarily due to a tax benefit from a change in estimate of accrued interest on uncertain tax positions.
• Cash provided by operating activities for the six months increased by $69 million to $2.01 billion.
• Free cash flow for the six months was $1.04 billion, a 2.1% increase year-over-year.
• The company repurchased 5 million shares for approximately $495 million during the six months ended October 24, 2025, at an average price of $91.37 per share.
• The U.S. Court of Appeals for the Federal Circuit ruled in favor of Medtronic, reversing a $106 million jury verdict in the Colibri patent litigation.

Sentiment

Score: 8

Explanation: The company reported strong revenue and earnings growth across key segments, favorable legal outcomes, and progress on strategic initiatives like the Diabetes separation. While some macroeconomic risks and legal uncertainties persist, the overall financial performance and operational highlights are positive.

Positives

• Net sales increased by 7% for the three months and 8% for the six months ended October 24, 2025, demonstrating strong top-line growth.
• Diluted EPS grew by 8.1% for the quarter and 4.5% for the six months, indicating improved profitability.
• Operating profit increased by 5.7% for the quarter and 9.0% for the six months, reflecting operational efficiency.
• Net cash provided by operating activities increased by $69 million to $2.01 billion for the six months, showing healthy cash generation.
• Free cash flow for the six months was $1.04 billion, up 2.1% from the prior year.
• The effective tax rate decreased significantly to 13.5% for the quarter due to a tax benefit from a change in estimate of accrued interest on uncertain tax positions.
• Cardiovascular segment net sales increased by 11% for the quarter and 10% for the six months, driven by strong growth in Cardiac Ablation Solutions (PulseSelect, Affera Sphere-9), TAVR (Evolut FX+), and Cardiac Rhythm Management (Micra, Aurora EV-ICD).
• Neuroscience segment net sales increased by 5% for the quarter and 4% for the six months, with strong performance in Neuromodulation (Inceptiv, Percept RC) and Cranial and Spinal Technologies (AiBLE ecosystem).
• Diabetes segment net sales grew by 10% for the quarter and 11% for the six months, primarily due to international adoption of the MiniMed 780G AID system.
• The U.S. Court of Appeals for the Federal Circuit reversed a $106 million jury verdict against Medtronic in the Colibri patent litigation, vacating the infringement ruling.
• The Italian government formalized a legislative decree in August 2025, reducing the Italian payback liability for years 2015-2018, resulting in a $39 million increase to net sales for the six months ended October 24, 2025.

Negatives

• Net losses on minority investments were $24 million for the quarter and $137 million for the six months ended October 24, 2025, compared to net gains in the prior year, primarily driven by a $90 million loss on the Mozarc Medical investment.
• Interest income decreased to $89 million for the quarter and $208 million for the six months, down from $137 million and $249 million respectively, due to changes in global liquidity structures.
• Cost of products sold as a percentage of net sales was partially offset by increased duties from tariffs on imported goods.
• Selling, general, and administrative expense increased due to higher selling expenses, new product launches, increased incentive performance, and costs supporting the Diabetes Operating Unit separation.
• Net cash used in financing activities increased by $511 million for the six months, primarily due to debt repayments and share repurchases, partially offset by new debt issuances.

Risks

• Competitive product launches and pricing pressure could negatively impact business.
• Geographic macroeconomic developments, including changes in global trade policies and currency exchange rates, pose risks.
• General price inflation and changes in interest rates could affect financial performance.
• Reimbursement challenges and impacts from changes in the mix of product offerings are potential headwinds.
• Delays in product registration approvals and national/provincial tender pricing for certain products, particularly in China, present risks.
• Replacement cycle challenges and supply chain disruptions could occur.
• The evolving nature of international trade policy, including tariffs, presents a risk to the cost structure and financial performance, with an estimated pre-tax net tariff impact of $185 million in fiscal year 2026.
• The Russia-Ukraine conflict and Israel's conflict, while not materially impacting current financials (less than 1% of revenues/assets), could have unpredictable long-term implications.
• Outcomes of legal actions, including product liability (Hernia Mesh, Diabetes Pump Retainer Ring), intellectual property, antitrust (Applied Medical), environmental, and anti-corruption matters, are uncertain and could have a material adverse impact.
• The ultimate cost of site cleanup and timing of future cash flows for environmental remediation matters are difficult to predict.
• Discussions are ongoing between the Italian government and industry groups related to the applicability of the Italian payback legislation for years 2019 and beyond, which could materially differ from the amount currently accrued.
• The Mallinckrodt bankruptcy litigation, alleging fraudulent transfer and alter ego liability, is proceeding to discovery, with potential for material adverse impact.

Future Outlook

Medtronic anticipates continued global penetration of its Micra transcatheter pacing portfolio and adoption of Aurora EV-ICD. The company expects growth from its innovative EP segment products, including PulseSelect and Affera mapping and ablation systems. Continued acceptance and growth are projected for the self-expanding CoreValve Evolut TAVR platform and the Symplicity Spyral renal denervation system following CMS's finalized National Coverage Determination. In Neuroscience, continued adoption of the AiBLE ecosystem and innovative spine products is expected, along with growth in Pelvic Health and ENT therapies. For Medical Surgical, the company aims for continued growth in Open-to-MIS techniques, powered stapling, and the Hugo robotic assisted surgery (RAS) system, with future U.S. FDA approval for Hugo RAS system and AI adoption in Endoscopy. The Diabetes business separation is expected to be completed within 18 months of the May 2025 announcement, with continued acceptance and growth for the MiniMed 780G system and Simplera sensor. The company estimates a pre-tax net tariff impact of $185 million in fiscal year 2026, with most of it in the second half.

Management Comments

• "Medtronic is the leading global healthcare technology company – alleviating pain, restoring health, and extending life for millions of people around the world."
• "We remain committed to deliver the best possible experiences for patients, physicians, and caregivers we serve; to create technologies that expand what's possible across the human body to transform lives; to turn data and insights into real action to serve patient needs, improving care; and to expand healthcare access and deliver positive outcomes."
• "Our goal is to continue to leverage selling, general, and administrative expense management initiatives."
• "We are currently in a strong financial position, and we believe our balance sheet and liquidity as of October 24, 2025, provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs."

Industry Context

Medtronic's strong performance in Cardiovascular, Neuroscience, and Diabetes segments reflects a robust demand for innovative medical devices and therapies. The growth in Cardiac Ablation Solutions, TAVR, and Neuromodulation aligns with broader industry trends towards less invasive procedures and advanced therapeutic solutions. The company's focus on AI-driven technologies and integrated solutions like the AiBLE ecosystem positions it well within the evolving healthcare technology landscape. The impending separation of the Diabetes business is a strategic move to potentially unlock value and allow both entities to focus on their core strengths, a trend seen in other diversified healthcare conglomerates. The macroeconomic and geopolitical factors, including tariffs and conflicts, highlight the global challenges faced by large multinational medical device companies, necessitating proactive mitigation strategies.

Comparison to Industry Standards

• Medtronic's 7% and 8% net sales growth for the three and six months, respectively, indicates a strong performance, potentially outpacing some competitors in the medical device sector, especially given the macroeconomic headwinds.
• The significant growth in Cardiac Ablation Solutions, particularly with PulseSelect and Affera Sphere-9 pulsed field ablation, suggests Medtronic is a leader in this rapidly evolving area, competing with companies like Boston Scientific and Johnson & Johnson's Biosense Webster.
• The continued acceptance and growth of the Evolut TAVR platform positions Medtronic strongly against competitors such as Edwards Lifesciences in the transcatheter aortic valve replacement market.
• The U.S. FDA approval and CE Mark for the Evolut FX+ TAVR system and the U.S. FDA approval for the Affera mapping and ablation system with Sphere-9 catheter demonstrate Medtronic's ability to bring competitive, innovative products to market, maintaining its leadership in key therapeutic areas.
• The finalization of National Coverage Determination by CMS for the Symplicity Spyral renal denervation system is a critical step for market acceptance, potentially allowing Medtronic to establish a strong position in the hypertension treatment market, an area with significant unmet needs.
• The growth in Neuromodulation, driven by products like Inceptiv and Percept RC, indicates Medtronic's competitive edge in chronic pain and movement disorder therapies against rivals like Abbott and Boston Scientific.
• The ongoing development and anticipated U.S. approval of the Hugo RAS system suggest Medtronic is actively expanding its presence in the robotic-assisted surgery market, competing with established players like Intuitive Surgical and newer entrants.

Corporate Governance

Legal Proceedings

• The U.S. Court of Appeals for the Federal Circuit ruled in favor of Medtronic on July 18, 2025, reversing a jury verdict of approximately $106 million in patent litigation brought by Colibri Heart Valve LLC, vacating the finding of infringement.
• Approximately 10,000 individual plaintiffs have filed lawsuits against Medtronic subsidiaries alleging personal injury from hernia mesh products, with no expense recorded as a potential loss is not probable and reasonably estimable.
• Seven lawsuits have been filed on behalf of 14 individuals in the Diabetes Pump Retainer Ring litigation, with certain litigation charges recognized in the first quarter of fiscal year 2026.
• Medtronic is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation, with a motion for summary judgment denied and trial set to begin on or shortly after January 20, 2026; no expense has been recorded as a potential loss is not probable and reasonably estimable.
• Medtronic is involved in environmental remediation matters at various sites, including Orrington, Maine, with accrued expenses included in accrued litigation.
• The company is a successor to a party named in a lawsuit relating to mercury contamination of the Penobscot River and Bay, with a settlement approved in October 2022.
• Medtronic engages in periodic discussions with governmental agencies regarding anti-corruption matters in different global markets; no expense has been recorded as a potential loss is not probable and reasonably estimable.
• The Italian Constitutional Court ruled the medical device payback law constitutional in July 2024, leading to a $90 million increase in liability for Medtronic in the prior year, but a legislative decree in June 2025 (formalized August 2025) reduced the liability for 2015-2018 by $39 million.
• Medtronic affiliates are defendants in a lawsuit brought by a trust in the Mallinckrodt PLC bankruptcy, with claims alleging actual fraudulent transfer and alter ego liability proceeding to discovery; no liability has been recorded as a potential loss is not probable and reasonably estimable.
• IRS audits regarding the allocation of income between Medtronic, Inc. and its Puerto Rico subsidiary are ongoing, with the U.S. Court of Appeals remanding the case back to the Tax Court for additional proceedings in September 2025.

Related Party Transactions

• Medtronic has entered into various arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C. to receive funding for the development of certain products within the Cardiovascular Portfolio and Diabetes Operating Unit. Medtronic recognized income of $37 million and $73 million during the three and six months ended October 24, 2025, respectively, from these arrangements.
• Following potential U.S. regulatory approval and commercial launch of products covered by Blackstone agreements, Blackstone will earn fixed regulatory and commercial milestone payments up to $1.2 billion and royalties based on a percentage of sales.

Stakeholder Impact

• Shareholders: Positive impact from increased net sales, net income, and EPS, along with continued share repurchase program. Potential for value creation from the Diabetes business separation. Risks from ongoing litigation and macroeconomic factors could impact share price.
• Employees: Restructuring charges primarily relate to employee termination benefits, indicating some workforce adjustments. The impending separation of the Diabetes business will create a new independent company, affecting employees in that unit.
• Customers: Continued introduction of innovative products (e.g., PulseSelect, Evolut FX+, Inceptiv, MiniMed 780G) aims to improve patient care and outcomes. Regulatory approvals and market acceptance are crucial for product availability.
• Suppliers: Supply chain challenges are noted as a macroeconomic risk, potentially impacting supplier relationships and operational continuity.
• Creditors: The company maintains a strong financial position with $29.1 billion in total debt, commercial paper programs, and a $3.5 billion credit facility, indicating good liquidity and ability to meet obligations. Recent debt issuances and repayments demonstrate active debt management.

Next Steps

• Complete the separation of the Diabetes business into a new independent, publicly traded company within 18 months of the May 2025 announcement.
• Continue to monitor the Colibri patent litigation until all additional appellate periods have expired.
• Proceed to discovery into the merits of the Trust's intentional fraudulent transfer and related claims in the Mallinckrodt bankruptcy litigation.
• Prepare for trial in the antitrust litigation brought by Applied Medical Resources Corporation, set to begin on or shortly after January 20, 2026.
• Continue additional proceedings in the IRS income allocation case for fiscal years 2005 and 2006, as remanded by the Appellate Court.
• Evaluate the potential effect of ASU 2023-09 (Income Taxes) on financial statement disclosures for adoption in Q4 FY26.
• Evaluate the potential effect of ASU 2024-03 (Disaggregation of Income Statement Expenses) on financial statement disclosures for adoption in Q4 FY28.
• Evaluate the potential effect of ASU 2025-06 (Internal-Use Software) on financial statements for adoption in Q1 FY29.
• Continue to take proactive steps to mitigate the effects of tariffs and manage other macroeconomic and geopolitical risks.
• Focus on continued global penetration of Micra transcatheter pacing portfolio and adoption of Aurora EV-ICD.
• Drive acceptance and growth of innovative EP segment products, including PulseSelect and Affera mapping and ablation systems.
• Promote market acceptance and reimbursement for the Symplicity Spyral renal denervation system.
• Continue adoption and growth of integrated solutions through the AiBLE offering in Neuroscience.
• Expand presence in robotic-assisted surgery with the Hugo RAS system, including seeking U.S. FDA approval.

Key Dates

Recommendation

Medtronic's Q2 FY26 results demonstrate strong operational performance with significant growth in net sales and diluted EPS, driven by key product innovations and market acceptance across its Cardiovascular, Neuroscience, and Diabetes segments. The favorable resolution of the Colibri patent litigation and the reduction in Italian payback liability are positive catalysts. While macroeconomic headwinds and ongoing legal challenges exist, the company's robust pipeline, strategic separation of the Diabetes business, and commitment to shareholder returns through dividends and share repurchases, coupled with a strong balance sheet, suggest a positive outlook for long-term investors. The company's ability to navigate complex regulatory and geopolitical landscapes, while continuing to innovate, supports a 'buy' recommendation.

Keywords

Medical Technology, Healthcare, SEC Filing, Earnings, Revenue, EPS, Cardiovascular, Neuroscience, Medical Surgical, Diabetes, Product Launches, Regulatory Approvals, Litigation, Tariffs, Debt, Cash Flow, Share Repurchase, Global Minimum Tax, Diabetes Separation